MH

Michael Henry

CBO at Aldatu Biosciences | Leader in adaptive PCR diagnostics for global health and emerging diseases

Berkeley, California

Invests in

Stages:

  • Min Investment:

    $5,000.00
  • Max Investment:

    $50,000.00
  • Target Investment:

    $25,000.00

Work Experience

  • Chief Business Officer

    2020

  • Member

    2017

  • Senior Vice President and General Manager, Consumer Genomics

    2016 - 2018

    Reporting to the CEO, led strategy, marketing, operations, new product development, financing and deal making for the consumer genomics business at Centrillion. • Negotiated a TeloYears Advanced Ancestry DNA test agreement with Telomere Diagnostics.

2015 - 2016

  • Vice President, Business Development

    2015 - 2016

    Led business development for AncestryDNA and AncestryHealth, subsidiaries of Ancestry, a $683 million 2015 revenue consumer internet company and leader in online genealogy and consumer genomics. • Sold Ancestry to Silver Lake and GIC for $2.6 billion in 2016. • Led the team that managed the longevity therapeutics target discovery collaboration with Calico, an Alphabet / Google company. • Secured a genotyping test services collaboration agreement with Quest Diagnostics.

2014 - 2015

  • Board of Directors

    2014 - 2015

  • Member

    2014 - 2015

  • Vice President, Business Development

    2013 - 2014

    Led business development for the General Health and Wellness franchise, a $1.8 billion 2012 revenue segment of Quest Diagnostics, a $7.2 billion 2012 revenue diagnostics laboratory. • Acquired Summit Health, a provider of on-site wellness programs for employers, health plans and retail clinics, for $113 million plus a $25 million contingent payment.

  • Vice President, Business Development

    2004 - 2013

    Reporting to the CEO, led business development including mergers, acquisitions, divestitures, patents, licensing, strategic planning, launching new businesses and supervision of five staff for a $110 million 2010 revenue genetic testing laboratory. • Sold Athena to Quest Diagnostics for $740 million in 2011. • Sold Athena to Fisher Scientific for $283 million in 2006. • Licensed and/or launched 271 new products during 2004-2012 achieving double digit new product sales growth.

2008 - 2008

  • Board of Directors

    2008 - 2008

2003 - 2003

  • CEO

    2003 - 2003